Harmonization of monographic standards is needed to ensure the quality of Chinese medicinal materials by Chan, Kelvin et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Chinese Medicine
Open Access Commentary
Harmonization of monographic standards is needed to ensure the 
quality of Chinese medicinal materials
Kelvin Chan*1, Kelvin Sze-Yin Leung*2 and Sandy Shuo Zhao2
Address: 1Department of Pharmacy, School of Applied Sciences, University of Wolverhampton, Wolverhampton WV1 1LY, UK and 2Department 
of Chemistry, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong, PR China
Email: Kelvin Chan* - prof.kchan@wlv.ac.uk; Kelvin Sze-Yin Leung* - s9362284@hkbu.edu.hk; Sandy Shuo Zhao - os6@live.hk
* Corresponding authors    
Abstract
This article provides an overview on the regulations of Chinese medicinal materials (CMMs) in
various countries and regions. Harmonization of CMM monographs would provide standards for
the quality control of CMM products and play an important role in the modernization and
globalization of Chinese medicine. A harmonized regulatory system would improve the quality of
CMMs thereby ensuring the safety of the products and assisting Chinese medicine practitioners in
their practice. The fast growing demand worldwide for traditional medicines calls for harmonized
monographic standards to safeguard the safety and quality of CMM products.
Background
Seventy to eighty percent of the world population relies
on non-conventional medicines (mainly of herbal
sources) as their primary health care [1]. Chinese medici-
nal materials (CMMs) have the highest turnover-trading-
figure among all herbal medicines [1].
At present there is a lack of methodology for the quality
control of CMMs. Most pharmacopoeias merely state the
minimum requirements to safeguard public safety. To
prevent adulterated CMMs, manufacturers must adopt
adequate quality control of international standards for
harvesting, collecting, processing and packing of the crude
herbs and final products. Licensing and registration of
herbal medicine are required to enforce the quality assess-
ment of CMMs. Specific monographic profiles of CMMs
can standardize the authentication and quality assess-
ment for CMM manufacturers worldwide.
Herbal standards around the world
Differences among national or regional regulations on
import and export of medicinal plants can affect the qual-
ity control of herbal products. Same medicinal plant
products may be classified as food, food-supplements,
functional food, nutriceuticals or prescription herbal
medicines in different countries or regions. The key fea-
tures of such diversified national and regional practices
due to different monographic standards on CMM prod-
ucts are summarized in Table 1.
World Health Organization
Over the years, the World Health Organization (WHO)
has introduced monographs of medicinal plants used
around the world. WHO also maintains a list of herbs that
are widely used in primary health care in various countries
as a result from the WHO Guidelines for the Assessment of
Herbal Medicines which promotes the development of
monographs to standardize the quality control of herbal
medicines. Twenty-five monographs encompassing 28
plants have been published in Volume I [2] and mono-
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graphs of 30 plants have been included in Volume II [3].
WHO emphasizes that these publications are not
'intended to replace official compendia such as pharma-
copoeias, formularies, or legislative documents but to
promote harmonization in the use of herbal medicines
with respect to levels of safety, efficacy, and quality con-
trol' [3].
Mainland China
China's first drug control law was promulgated in 1984
[4]. According to the law, production of a new drug is sub-
ject to approval by the Drug Regulatory Department
under the State Council. The drug regulatory department
has compiled a list of crude Chinese medicines. A manu-
facturer may start producing a drug after a registered
number is granted. If a manufacturer modifies the produc-
tion process, approval from the authorities is necessary.
Pharmacopoeia of the People's Republic of China [5] is com-
piled by the Drug Regulatory Department according to the
national drug standards in China [6]. The Drug Adminis-
tration Law of the People's Republic of China was imple-
mented in 2002 [7].
Good Agricultural Practice (GAP) is also applicable to the
quality control of Chinese crude drugs [8] as it includes
quality aspects such as macroscopic/microscopic authen-
tication, chemical identification, bioactive compounds
and metal elements, as well as pesticide detection. Micro-
scopic examination/authentication identifies the charac-
teristics of tissues, cells or cell contents in sections,
powders or surface on slides of CMMs. Chemical identifi-
cation should include high performance liquid chroma-
tography (HPLC) fingerprints and Fourier transform
infrared spectroscopy (FTIR) in investigation stage [9].
Bioactive compounds should be assayed [10]. In China,
the authorities have implemented GAP for the cultivation
of over 80 species of commonly used CMMs in regions
where CMM plants are traditionally cultivated. Outside
China CMM plants are cultivated to meet the increasing
demand; however, no consensus in methodology has
been reached as to how effective regulation can reflect the
multi-bioactivity aspects of CMMs [11].
Australia
Therapeutic Goods Administration (TGA) under the
Commonwealth Department of Health is the national
therapeutic goods control authority in Australia. The Aus-
tralian Regulatory Guidelines for Complementary Medicines
(ARGCM) [12] is used to regulate Chinese medicine
which is classified as a complementary medicine [13]. The
regulatory framework for complementary medicines in
Australia is a two-tier one, classifying registered medicines
into high risk or low risk groups [14]. Risk assessment is
conducted on ingredients, indications and claims, dosage
form, significance of side effects and effects of prolonged
use or from inappropriate self-medication. Therapeutic
Goods Act 1989 requires that therapeutic goods available
in Australia should be included in the Australian Register
of Therapeutic Goods (ARTG), unless they are specifically
exempted from this requirement by Schedule 5 of the
Therapeutic Goods Regulations 1990 [13].
Continental Europe
In 1964, Belgium, France, Germany, Italy, Luxembourg,
the Netherlands, Switzerland and the United Kingdom
signed the Convention on the Elaboration of a European
Pharmacopoeia  which has been ratified in 31 European
states [15]. European Pharmacopoeia is now a standard ref-
erence for both European and non-European countries
[16] and published by the European Directorate for the
Quality of Medicines and Healthcare (EDQM) [17]. Euro-
pean Pharmacopoeia is known for its universal requirement
of all medicines regardless of their origins [15]. About 130
herbal medicines including drugs and drug preparations
are included in the European Pharmacopoeia [15]. All nec-
essary tests and assay methods described in the mono-
graph were rigorously validated according to the Technical
Guide [18]. In response to toxicity incidences of herbal
products, the European Commission requested that the
monographs on herbal drugs used in traditional Chinese
medicine should be developed to achieve a modern qual-
ity standard according to the European Pharmacopoeia, and
listed the herbal drugs subject to investigation [19]. Cur-
rently the emphasis has been placed on compiling a list of
all herbal drugs subject to investigation. The European
Table 1: Pharmacopoeia or standards of various countries or regions that have monographic standards for CMMs
Pharmacopoeia and monograph Authority Status
WHO Monographs on Selected Medicinal Plants World Health Organization Unofficial
Chinese Pharmacopoeia State Food and Drugs Administration, China Official
Australian Regulatory Guidelines for Complementary Medicines Therapeutic Goods Administration, Australia Official
European Pharmacopoeia European Directorate for Quality Medicines and Healthcare Official
Hong Kong Chinese Materia Medica Standards Department of Health, Hong Kong, China Official
Japanese Pharmacopoeia Pharmaceutical Affairs, Japan Official
Thai Herbal Pharmacopoeia Thai Food and Drug Administration, Thailand Official
British Pharmacopoeia British Pharmacopoeia Commission, UK Official
American Herbal Pharmacopoeia (AHP) USA UnofficialChinese Medicine 2009, 4:18 http://www.cmjournal.org/content/4/1/18
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Pharmacopoeia Commission is producing more and
more monographs and elaborating monographs on pro-
prietary drugs [19].
Hong Kong, China
In 1999, the statutory status was accorded to Chinese
medicine in Hong Kong and the Chinese Medicine Coun-
cil of Hong Kong (CMC) was established [20] to regulate
Chinese herbal medicines with assistance from the Chi-
nese Medicine Division of the Department of Health [21].
All proprietary Chinese medicines (PCMs) manufactured
or sold in Hong Kong must be registered. For PCMs regis-
tered under 'new drug category', additional supporting
information such as acute/chronic toxicities should also
be provided [20].
In 2001, the Department of Health published the Hong
Kong Chinese Materia Medica Standards (HKCMMS) [22]
which is currently the only standard that has comprehen-
sive limits for heavy metals, pesticide residues and myco-
toxins across all monographs (Table 2). All analytical
methods and parameters under the HKCMMS were
advised by the International Advisory Board (IAB) after
considering all the data generated by research efforts from
experts of the six universities in Hong Kong. In addition,
a Scientific Committee, consisting of IAB members and
representatives of the participating universities and gov-
ernment departments, were set up to resolve technical
issues and examine research results. All limits were deter-
mined with ten samples and with reference to the Chinese
Pharmacopoeia, British Pharmacopoeia, European Pharmaco-
poeia, Japanese Pharmacopoeia and US Pharmacopoeia [22]
(Table 2).
Japan
In Japan, Kampo medicine refers to Chinese medicine and
Japanese indigenous medicine [23]. Kampo formulae had
been non-prescription medicines until 1985 when certain
Kampo medicines became classified as prescription medi-
cines and are therefore subject to clinical evaluation [24].
A total of 148 Kampo formulae have been approved for
clinical use in Japan. The monographs of the top 20
Kampo extracts have been published in the latest version
of the Japanese Pharmacopoeia as the official standards for
the medically significant herbal substances [25].
Thailand
In Thailand, medicinal plant materials or crude drugs
used in traditional medicines are exempt from registration
for easy public use [26]. Prior to the production of any tra-
ditional medicine, manufacturers must apply for the man-
ufacturing licenses from the Thai Food and Drug
Administration [27]. The registration requires informa-
tion on the raw material or ingredients, method of proc-
ess, dosage and quality control. Furthermore, safety
information related to acute, sub-chronic and chronic tox-
icity test as well as clinical trials results should be provided
[28]. Thai Herbal Pharmacopoeia is published by the sub-
committee on the establishment of the Thai Herbal Phar-
macopoeia  under the supervision of the Thai
Pharmacopoeia Committee [29]. Thai Herbal Pharmaco-
poeia  covers 23 monographs of Thai medicinal plant
materials and three herbal preparations. Currently, com-
pliance with the GMP and other standards for the manu-
facture of traditional medicines are voluntary; however,
traditional medicines submitted for registration must pass
the limited tests of microbiology, heavy metal and pesti-
Table 2: Hong Kong Chinese Materia Medica Standards recommended limits of heavy metals, pesticide residues and mycotoxins
Heavy metal Limits
Arsenic 2.0 mg/kg
Cadmium 0.3 mg/kg
Lead 5.0 mg/kg
Mercury 0.2 mg/kg
Pesticide
Aldrin and Dieldrin (sum of) 0.05 mg/kg
Chlordane (sum of cis- trans- and oxychlordane) 0.05 mg/kg
DDT (sum of p,p"-DDT, o,p'-DDT, p,p'-DDE and p,p'-TDE 1.0 mg/kg
Endrin 0.05 mg/kg
Heptachlor (sum of heptachlor and heptachlor epoxide) 0.05 mg/kg
Hexachlorobenzene 0.1 mg/kg
Hexachlorocyclohexane isomers (α-, β- and δ-hexachlorocyclohexane) 0.3 mg/kg
Lindane (γ-Hexachlorocyclohexane) 0.6 mg/kg
Quintozene (sum of quintozene, pentachloroaniline and methyl pentachlorophenyl sulphide) 1.0 mg/kg
Mycotoxin
Aflatoxin B1 5 μg/kg
Aflatoxins (sum of B1, B2, G1 and G2) 10 μg/kgChinese Medicine 2009, 4:18 http://www.cmjournal.org/content/4/1/18
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cide residues. In addition, the Thai Food and Drug
Administration is a member of the Uppsala Monitoring
Center Network responsible for the surveillance of the
safety of health care products [29].
United Kingdom
In the United Kingdom, there are three regulatory routes
for herbal medicines: unlicensed herbal remedies, regis-
tered Traditional Herbal Medicines (THMs) and licensed
herbal medicines [30]. Herbal products do not have to
meet specific standards of safety and quality. Registered
THMs are regulated by the Traditional Herbal Medicines
Registration Scheme and are required to meet specific
safety and quality standards and to be accompanied by
agreed indications. Licensed herbal medicine must have a
product license or marketing authorization. British Phar-
macopoeia  contains approximately 3100 monographs
whereby all medicines and health care products are regu-
lated [31]. CMMs are classified under the herbal and com-
plementary medicines division in the British
Pharmacopoeia.
At present, the British Pharmacopoeia contains 13 mono-
graphs of traditional herbal medicines which facilitate
assessment of registration applications and gives a refer-
ence standard to inform the manufacturers and importers
of the UK regulations. For the first time, a monograph of
Radix et Rhizoma Glycyrrhizae (Gancao, Liquorice root), a
Chinese medicinal herb, was introduced into the British
Pharmacopoeia. Furthermore, collaboration has been
established between the British and Chinese Pharmaco-
poeias in order to exchange information on quality stand-
ards for medicines, develop test methods, identify
common adulterants or impurities and to authenticate
herbal materials [32].
United States
In the United Sates, CMMs are classified as supplementary
products regulated by the Dietary Supplements Health
and Education Act (DSHEA) [33]. A manufacturer must
guarantee that the product is safe and properly labeled.
While approval from the Food and Drug Administration
is not required, new dietary ingredients are required for
pre-market safety review [33]. Overall, the regulation for
dietary supplements is less stringent than that for drugs.
In the United Sates, the American Herbal Pharmacopoeia
(AHP) publishes monographs for herbs used as dietary
supplements. AHP offers standard herbal monographs
whereby a genus and species may be identified according
to the Lingnean system of botanical classification and
nomenclatures [34]. AHP also produces monographs on
herbs and other botanical ingredients, not necessarily
already in the AHP [35]. AHP has published several mon-
ographs on botanicals in its dietary supplement section
[34].
Discussion
The present article provides an overview on the regula-
tions of CMMs in various countries and regions. Each
individual regulation system focuses on specific issues. In
the United Sates, regulation places its emphasis on source
herbal materials. In the European Union, procedures
focus on authentication of herbal materials. The European
Medicine Evaluation Agency comprising EU member
states was formed for managing the European Pharmaco-
poeia. A Technical Guide was issued with all technical
details on the scientific works developed for those medic-
inal materials under regulations. In Australia, TGA regu-
lates all the registered products in terms of the quality,
safety and efficacy. In the UK, regulation focuses on safety
evaluation. In China, the regulation is directed to proper
formulation of CMM products according to traditional
Chinese medicine theory. Under the present systems
herbal manufacturers can submit their products according
to the ease of getting registration in the regions where they
can market or sell their products. One of the Chinese med-
icine practices is composite herbal formulae (Fufang) for
individualized treatment. If the quality of CMMs is not
standardized, treatment variability will exist in addition to
other variables. It is imperative, therefore, for regulatory
agencies worldwide to set up harmonized regulatory con-
trols over the manufacture and trade of CMMs.
Conclusion
The fast growing demand worldwide for traditional med-
icines calls for harmonized monographic standards to
safeguard the safety and quality of CMM products.
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